ECSP11010782A - Derivados de 4,5-dihidro-oxazol-2-ilo - Google Patents
Derivados de 4,5-dihidro-oxazol-2-iloInfo
- Publication number
- ECSP11010782A ECSP11010782A EC2011010782A ECSP11010782A ECSP11010782A EC SP11010782 A ECSP11010782 A EC SP11010782A EC 2011010782 A EC2011010782 A EC 2011010782A EC SP11010782 A ECSP11010782 A EC SP11010782A EC SP11010782 A ECSP11010782 A EC SP11010782A
- Authority
- EC
- Ecuador
- Prior art keywords
- halogen
- disorders
- lower alkyl
- chr
- substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical group 0.000 abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- -1 nitro, hydroxy Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 230000009045 body homeostasis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La invención se está relacionada con compuestos de fórmulaIen el queR1 es hidrógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, halógeno, ciano, nitro, hidroxi, C(O)O-alquilo inferior, S(O)2-alquilo inferior, C(O)OCH2-fenilo, OCH2-fenilo, tetrazol-1-ilo, fenilo opcionalmente sustituido por halógeno, o es feniloxi opcionalmente sustituido por halógeno, o es bencilo opcionalmente sustituido por halógeno o es benciloxi opcionalmente sustituido por halógeno, en el que los sustituyentes para n> 1 pueden ser el mismo o diferente;X es -O-(CH2)2-, -O-CHR''-CH2-, -O-CH2-CHR', -O-CR''2-CH2-, -(CH2)2-CHR', -CHR'-(CH2)2-,-CR''2-(CH2)2-, -CH2-CHR'-CH2-, -CH2-CR''2-CH2-, -CHR''-O-CH2-,-CH2-O-CH2-, -CR''2-O-CH2-,-CF2(CH2)2-, -CR''2-CH2-, -SiR''2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-,o ;para m siendo 0, 1, 2 o 3;R' es alquilo inferior, alcoxi inferior o alquilo inferior sustituido por halógeno;R'' es alquilo inferior o alquilo inferior sustituido por halógeno;R2 es hidrógeno o alquilo inferior;Y es arilo, cicloalquilo o heteroarilo;n es 1, 2 o 3;o una sal de adición ácida farmacéuticamente adecuada.Los compuestos descritos en la presente fórmula I pueden utilizarse para el tratamiento de enfermedades relacionadas con la función biológica de los receptores asociados a aminas traza, cuyas enfermedades son la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención por hiperactividad, trastornos relacionados con el estrés, trastornos psicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migraña, abuso de sustancias y trastornos metabólicos, trastornos alimenticios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo de energía y asimilación, trastornos y disfunción de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano, y trastornos cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161060 | 2008-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11010782A true ECSP11010782A (es) | 2011-02-28 |
Family
ID=41066683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011010782A ECSP11010782A (es) | 2008-07-24 | 2011-01-24 | Derivados de 4,5-dihidro-oxazol-2-ilo |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20100041686A1 (es) |
| EP (1) | EP2321287B1 (es) |
| JP (1) | JP5547187B2 (es) |
| KR (1) | KR101307007B1 (es) |
| CN (1) | CN102083805A (es) |
| AR (1) | AR072876A1 (es) |
| AU (1) | AU2009273324A1 (es) |
| BR (1) | BRPI0916363A2 (es) |
| CA (1) | CA2728480A1 (es) |
| CL (1) | CL2011000137A1 (es) |
| CO (1) | CO6331336A2 (es) |
| CR (1) | CR11843A (es) |
| EC (1) | ECSP11010782A (es) |
| ES (1) | ES2556633T3 (es) |
| IL (1) | IL209423A0 (es) |
| MA (1) | MA32486B1 (es) |
| MX (1) | MX2011000464A (es) |
| PE (1) | PE20110215A1 (es) |
| RU (1) | RU2513086C2 (es) |
| TW (1) | TW201008916A (es) |
| WO (1) | WO2010010014A1 (es) |
| ZA (1) | ZA201008657B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009291602B2 (en) | 2008-09-11 | 2013-02-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| US8354441B2 (en) * | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| WO2011115928A1 (en) | 2010-03-15 | 2011-09-22 | Amgen Inc. | Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
| AU2011227511B2 (en) | 2010-03-15 | 2014-02-20 | Amgen Inc. | Spiro-tetracyclic ring compounds as Beta - secretase modulators |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US8673950B2 (en) * | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
| EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
| EP2758406A1 (en) | 2011-09-21 | 2014-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| MX377836B (es) | 2016-03-17 | 2025-03-11 | F Hoffmann La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida teniendo actividad como agonista de receptor asociado con aminas trazas (taar). |
| EP3452473A1 (en) * | 2016-05-04 | 2019-03-13 | Purdue Pharma L.P. | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof |
| WO2017210616A1 (en) * | 2016-06-02 | 2017-12-07 | Purdue Pharma L.P. | Trace amine associated receptor 1 agonists and partial agonists for pain treatment |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) * | 1956-01-17 | Nxg hi | ||
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) * | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| US2778836A (en) * | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744910A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2744909A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| DE1121054B (de) * | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| DE1150180B (de) * | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
| US3377247A (en) * | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) * | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
| BE754820R (fr) * | 1969-08-13 | 1971-02-15 | Schering Ag | Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs |
| US3818094A (en) * | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
| US3622579A (en) * | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
| US3660423A (en) * | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) * | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| US4125620A (en) * | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
| US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
| GB1538097A (en) * | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| US4311840A (en) * | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
| DE3377061D1 (en) * | 1982-06-03 | 1988-07-21 | Hoffmann La Roche | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives |
| DK302185A (da) * | 1984-07-05 | 1986-01-06 | Rolland Sa A | 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| DE19514579A1 (de) * | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US5610174A (en) * | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| US5866579A (en) * | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| CA2328973A1 (en) * | 1998-04-23 | 1999-10-28 | Akio Ojida | Naphthalene derivatives, their production and use |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| BRPI0516025A (pt) * | 2004-09-24 | 2008-08-19 | Allergan Sales Inc | 4-(heteroaril-metil e heteroaril-metil substituìda)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos |
| ATE458732T1 (de) * | 2006-01-27 | 2010-03-15 | Hoffmann La Roche | Verwendung von 4-imidazol-derivaten für zns- erkrankungen |
| WO2008092785A1 (en) * | 2007-02-02 | 2008-08-07 | F. Hoffmann-La Roche Ag | Novel 2-aminooxazolines as taar1 ligands for cns disorders |
-
2009
- 2009-07-15 CA CA2728480A patent/CA2728480A1/en not_active Abandoned
- 2009-07-15 RU RU2011104433/04A patent/RU2513086C2/ru not_active IP Right Cessation
- 2009-07-15 MX MX2011000464A patent/MX2011000464A/es not_active Application Discontinuation
- 2009-07-15 CN CN200980125666.7A patent/CN102083805A/zh active Pending
- 2009-07-15 KR KR1020117001611A patent/KR101307007B1/ko not_active IP Right Cessation
- 2009-07-15 EP EP09780600.4A patent/EP2321287B1/en active Active
- 2009-07-15 AU AU2009273324A patent/AU2009273324A1/en not_active Abandoned
- 2009-07-15 BR BRPI0916363A patent/BRPI0916363A2/pt not_active IP Right Cessation
- 2009-07-15 PE PE2011000063A patent/PE20110215A1/es not_active Application Discontinuation
- 2009-07-15 WO PCT/EP2009/059026 patent/WO2010010014A1/en active Application Filing
- 2009-07-15 ES ES09780600.4T patent/ES2556633T3/es active Active
- 2009-07-15 JP JP2011519122A patent/JP5547187B2/ja not_active Expired - Fee Related
- 2009-07-17 US US12/504,702 patent/US20100041686A1/en not_active Abandoned
- 2009-07-22 TW TW098124766A patent/TW201008916A/zh unknown
- 2009-07-23 AR ARP090102799A patent/AR072876A1/es unknown
-
2010
- 2010-11-18 IL IL209423A patent/IL209423A0/en unknown
- 2010-11-25 CO CO10148408A patent/CO6331336A2/es not_active Application Discontinuation
- 2010-12-01 ZA ZA2010/08657A patent/ZA201008657B/en unknown
- 2010-12-13 CR CR11843A patent/CR11843A/es not_active Application Discontinuation
-
2011
- 2011-01-18 MA MA33533A patent/MA32486B1/fr unknown
- 2011-01-21 CL CL2011000137A patent/CL2011000137A1/es unknown
- 2011-01-24 EC EC2011010782A patent/ECSP11010782A/es unknown
-
2012
- 2012-03-02 US US13/410,315 patent/US20120165294A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009273324A1 (en) | 2010-01-28 |
| JP5547187B2 (ja) | 2014-07-09 |
| MA32486B1 (fr) | 2011-07-03 |
| KR101307007B1 (ko) | 2013-09-11 |
| CL2011000137A1 (es) | 2011-07-15 |
| ES2556633T3 (es) | 2016-01-19 |
| WO2010010014A1 (en) | 2010-01-28 |
| RU2011104433A (ru) | 2012-08-27 |
| BRPI0916363A2 (pt) | 2018-05-29 |
| MX2011000464A (es) | 2011-03-01 |
| CR11843A (es) | 2011-02-16 |
| JP2011528685A (ja) | 2011-11-24 |
| IL209423A0 (en) | 2011-01-31 |
| EP2321287A1 (en) | 2011-05-18 |
| PE20110215A1 (es) | 2011-03-31 |
| US20100041686A1 (en) | 2010-02-18 |
| KR20110020936A (ko) | 2011-03-03 |
| CA2728480A1 (en) | 2010-01-28 |
| RU2513086C2 (ru) | 2014-04-20 |
| TW201008916A (en) | 2010-03-01 |
| CN102083805A (zh) | 2011-06-01 |
| CO6331336A2 (es) | 2011-10-20 |
| EP2321287B1 (en) | 2015-11-11 |
| AR072876A1 (es) | 2010-09-29 |
| ZA201008657B (en) | 2011-10-26 |
| US20120165294A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11010782A (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| BR112013024312A2 (pt) | derivados de amina heterocíclica | |
| MY176030A (en) | Substituted benzamide derivatives | |
| ECSP099551A (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para desordenes cns | |
| AR088741A1 (es) | Derivados de pirazol | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| EA201070903A1 (ru) | Замещенные спироциклические производные пиперидина как лиганды гистамин-3(h) рецептора | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| AR092537A1 (es) | Derivados de pirazol-carboxamida | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MX377195B (es) | Derivados de morfolina-piridina. | |
| AR059182A1 (es) | Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos | |
| MX2015005721A (es) | Derivados de pirazina. | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
| AR063811A1 (es) | 4-imidazoles sustituidos | |
| MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
| MX2016016606A (es) | Derivados de 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o de 3-aminocroman-7-ilo como moduladores de receptores asociados a aminastraza (taar). | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
| TH108796A (th) | อนุพันธ์ 4,5-ไดไฮโดร-ออกซาซอล-2-อิล |